Facebook Tracking Image

National Comprehensive Cancer Network

About NCCN

NCCN Flash Updates: NCCN Guidelines® and NCCN Compendium® for Central Nervous System Cancers and NCCN Guidelines® and NCCN Compendium® for Ovarian Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines® are currently available as Version 2.2019.

  • The following footnote was added to bevacizumab monotherapy for recurrent glioblastoma: An FDA-approved biosimilar is an appropriate substitute for bevacizumab.

Previous updates to the NCCN Guidelines for Central Nervous System Cancers can be found in the UPDATES section of the current version.

 

NCCN has published updates to the NCCN Guidelines, and the NCCN Compendium® for Ovarian Cancer. These NCCN Guidelines are currently available as Version 2.2019.

  • Footnote w has been revised: Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Testing recommended to include at least: BRCA1/2, and microsatellite instability or DNA mismatch repair if not previously done. Evaluation of homologous recombination deficiency can be considered. Additional somatic tumor testing can be considered at the physician’s discretion to identify genetic alterations for which FDA-approved tumor-specific or tumor-agnostic targeted therapy options exist.  (OV-6/7)
  • Recurrence therapy for Platinum-Sensitive (OV-C, 6 of 9) and Platinum-Resistant Disease (OV-C, 7 of 9)
    • The following targeted therapy options have been added under "useful in certain circumstances": Entrectinib or larotrectinib (for NTRK gene fusion-positive tumors)

Previous updates to the NCCN Guidelines for Ovarian Cancer can be found in the UPDATES section of the current version.

 

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Biomarkers Compendium®, the NCCN Chemotherapy Order Templates (NCCN Templates®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android smartphones & tablets are now available! Visit NCCN.org/apps

About NCCN Flash Updates™ 

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium®, and other NCCN Content. 

Subscribe to NCCN Flash Updates™ 

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

National Comprehensive Cancer Network® (NCCN®)

3025 Chemical Road, Suite 100

Plymouth Meeting, PA 19462

Telephone: +1 215.690.0300 Fax: +1 215.690.0280 

Access information on permissions and licensing of NCCN Content  

© 2019 National Comprehensive Cancer Network. All Rights Reserved.

Users may opt-out via e-mail or by updating their profile. Users may unsubscribe at any time by contacting us.

NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.